A study in the March 2015 issue of CGH finds that withdrawal of immunomodulators after at least 6 months of co-treatment with infliximab does not reduce the trough levels of infliximab in patients with Crohn's disease.

Clinical Gastroenterology & Hepatology

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Crohn's Disease Patients

An engaging mix of author interviews and expert commentary on the latest articles from Clinical Gastroenterology and Hepatology, hosted by the AGA journals' online editor, John F. Kuemmerle, MD, AGAF.

About

Clinical Gastroenterology & Hepatology